USRE33565EExpiredUtility
Prevention and treatment of rheumatioid arthritis
Priority: Feb 6, 1978Filed: Aug 11, 1988Granted: Apr 2, 1991
Est. expiryFeb 6, 1998(expired)· nominal 20-yr term from priority
A61K 38/00A61K 39/39508
17
PatentIndex Score
12
Cited by
51
References
4
Claims
Abstract
There is disclosed a novel method and product for the treatment and prevention of rheumatoid arthritis. The method involves passive immunization against a mixed spectrum of infectious bacteria which reside in the human gastrointestinal tract. The passive immunization is accomplished by oral.[.injestion.]. .Iadd.ingestion .Iaddend.of IgG immunoglobulin obtained from the milk of cows that have been immunized against a specific spectrum of bacterial types. A unique combination of bacterial species is formulated into a vaccine which is used to immunize dairy cattle. The IgG antibody obtained from the milk of the immunized cows constitutes the product of the invention.
Claims
exact text as granted — not AI-modifiedWe claim:
1. A method for the treatment of rheumatoid arthritis caused by a mixed spectrum of infectious bacteria which reside in the gastrointestinal tract, including: ______________________________________
ORGANISMS
______________________________________
Staphylococcus aureus
Staphylococcus epidermidis
Streptococcus pyogenes, A. Type 1
Streptococcus pyogenes, A. Type 3
Streptococcus pyogenes, A. Type 5
Streptococcus pyogenes, A. Type 8
Streptococcus pyogenes, A. Type 12
Streptococcus pyogenes, A. Type 14
Streptococcus pyogenes, A. Type 18
Streptococcus pyogenes, A. Type 22
Aerobacter aerogenes
Escherichia coli
Salmonella enteritidis
Pseudomonas aeruginosa
Klebsiella pneumoniae
Salmonella typhimurium
Haemophilus influenzae
Streptococcus viridans
Proteus vulgaris
Shigella dysenteriae
Streptococcus, Group B
Diplococcus pneumoniae
Streptococcus mutans
Corynebacterium, Acne, Types 1 & 2
______________________________________
which comprises the oral administration of a quantity of non-fat milk solids equivalent to one quart of immunized cow's milk I g G, .[.post-prandially.]. two times daily, wherein the cow's milk .[.IgG.]. includes antibodies produced by the following microorganisms from American Type Culture Collection bacterial antigens: ______________________________________
ORGANISM *ATCC NO.
______________________________________
Staphylococcus aureus 11631
Staphylococcus epidermidis
155
Streptococcus pyogenes, A. Type 1
8671
Streptococcus pyogenes, A. Type 3
10389
Streptococcus pyogenes, A. Type 5
12347
Streptococcus pyogenes, A. Type 8
12349
Streptococcus pyogenes, A. Type 12
11434
Streptococcus pyogenes, A. Type 14
12972
Streptococcus pyogenes, A. Type 18
12357
Streptococcus pyogenes, A. Type 22
10403
Aerobacter aerogenes 884
Escherichia coli 26
Salmonella enteritidis
13076
Pseudomonas aeruginosa
7700
Klebsiella pneumoniae 9590
Salmonella typhimurium
13311
Haemophilus influenzae
9333
Streptococcus viridans
6249
Proteus vulgaris 13315
Shigella dysenteriae 11835
Streptococcus, Group B
Diplococcus pneumoniae
Streptococcus mutans
Corynebacterium, Acne, Types 1 & 2
______________________________________
2. An antibody for the treatment of rheumatoid arthritis caused by a mixed spectrum of infectious bacteria which reside in the gastrointestinal tract, including: ______________________________________
ORGANISMS
______________________________________
Staphylococcus aureus
Staphylococcus epidermidis
Streptococcus pyogenes, A. Type 1
Streptococcus pyogenes, A. Type 3
Streptococcus pyogenes, A. Type 5
Streptococcus pyogenes, A. Type 8
Streptococcus pyogenes, A. Type 12
Streptococcus pyogenes, A. Type 14
Streptococcus pyogenes, A. Type 18
Streptococcus pyogenes, A. Type 22
Aerobacter aerogenes
Escherichia coli
Salmonella enteritidis
Pseudomonas aeruginosa
Klebsiella pneumoniae
Salmonella typhimurium
Haemophilus influenzae
Streptococcus viridans
Proteus vulgaris
Shigella dysenteriae
Streptococcus, Group B
Diplococcus pneumoniae
Streptococcus mutans
Corynebacterium, Acne, Types 1 & 2
______________________________________
produced by first preparing a vaccine from killed bacteria from the American Type Culture Collection bacterial antigens, including: ______________________________________
Staphylococcus aureus 11631
Staphylococcus epidermidis
155
Streptococcus pyogenes, A. Type 1
8671
Streptococcus pyogenes, A. Type 3
10389
Streptococcus pyogenes, A. Type 5
12347
Streptococcus pyogenes, A. Type 8
12349
Streptococcus pyogenes, A. Type 12
11434
Streptococcus pyogenes, A. Type 14
12972
Streptococcus pyogenes, A. Type 18
12357
Streptococcus pyogenes, A. Type 22
10403
Aerobacter aerogenes 884
Escherichia coli 26
Salmonella enteritidis
13076
Pseudomonas aeruginosa
7700
Klebsiella pneumoniae 9590
Salmonella typhimurium
13311
Haemophilus influenzae
9333
Streptococcus viridans
6249
Proteus vulgaris 13315
Shigella dysenteriae 11835
Streptococcus, Group B
Diplococcus pneumoniae
Streptococcus mutans
Corynebacterium, Acne, Types 1 & 2
______________________________________
injecting said vaccine intramuscularly in healthy cows once weekly for four consecutive weeks, and twice monthly thereafter, each injection involving 20×10 8 bacterial cells; collecting the milk from the immunized cows beginning the fourth week; and testing .[.fro.]. .Iadd.for .Iaddend.titer to insure that the minimum titer against each of the bacteria is 1-500, as determined by the tube agglutination method for testing antibody titer.
3. The preparation of claim 2, wherein the antibody product type IgG is pure immunoglobulin obtained from milk.
4. The method of preparing the antibody of claim 2 which includes preparing a vaccine from killed bacteria from the American Type Culture Collection bacterial antigens including: ______________________________________
Staphylococcus aureus 11631
Staphylococcus epidermidis
155
Streptococcus pyogenes, A. Type 1
8671
Streptococcus pyogenes, A. Type 3
10389
Streptococcus pyogenes, A. Type 5
12347
Streptococcus pyogenes, A. Type 8
12349
Streptococcus pyogenes, A. Type 12
11434
Streptococcus pyogenes, A. Type 14
12972
Streptococcus pyogenes, A. Type 18
12357
Streptococcus pyogenes, A. Type 22
10403
Aerobacter aerogenes 884
Escherichia coli 26
Salmonella enteritidis
13076
Pseudomonas aeruginosa
7700
Klebsiella pneumoniae 9590
Salmonella typhimurium
13311
Haemophilus influenzae
9333
Streptococcus viridans
6249
Proteus vulgaris 13315
Shigella dysenteriae 11835
Streptococcus, Group B
Diplococcus pneumoniae
Streptococcus mutans
Corynebacterium, Acne, Types 1 & 2
______________________________________
injecting said vaccine intramuscularly in healthy cows .[.and.]. weekly for four consecutive weeks, and twice monthly thereafter, each .[.injections.]. .Iadd.injection .Iaddend.involving 20×10 8 bacterial cells.[.,.]. .Iadd.; .Iaddend.collecting the milk from the immunized cows beginning the fourth week; and testing for titer to insure that the minimum titer of antibody against each of the bacteria is 1-500, as determined by the tube agglutination method for testing antibody titer.Join the waitlist — get patent alerts
Track USRE33565E — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.